Minimizing Patient Radiation Risk While Maintaining Image Quality

VirtualDose™CT is sophisticated radiation dose simulation software for radiologists, radiological technologists, medical physicists, regulators, manufacturers and researchers. Thanks to the use of a well-tested family of anatomically correct phantoms, revolutionary GPU-based Monte Carlo simulation, and innovative SaaS programming techniques, it permits radiation health professionals to obtain highly accurate images with much greater patient safety.


VirtualDoseCT enables users to assess organ doses, in addition to CTDI and DLP data provided by the CT scanner.  It is able to differentiate for individuals outside of the “average” population body habitus. It is ready for use with the latest CT scanners and with recent ICRP-60 and ICRP-103 recommendations on effective dose.

And we use the world’s most advanced patient models, including:Slide 1

  • Adults at various body weights and heights
  • Overweight and obese adults
  • Children at different ages and body sizes
  • Pregnant female at three gestational stages

VirtualDoseCT delivers:

  • The world’s largest library of patient phantoms
  • Organ dose data from validated CT scanners for each patient
  • An intuitive, easy-to-use graphical user interface
  • Web-based solution for easy access
  • Breakthrough accuracy and speed using the revolutionary GPU technology

Easy to Use, Web-Based. Currently available for x-ray computed tomography (CT) examinations, our easy-to-use radiation dose tool is accessed via the Web. There is no software to install or maintain. Your hospital or research center establishes an account in our database and then uses the software with each patient image to precisely calculate correct radiation dose based on actual patient morphology and the organ to be imaged.

Researched and Respected. VirtualDoseCT is the product of many years of research funded by the National Institutes of Health and other leading government agencies. Led by world-renowned researchers, the product has recently finished beta testing at more than 10 leading hospitals in the United States.